Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs

Despite proven benefits, prophylactic treatment for hemophilia A is hampered by the short half-life of factor VIII. A recombinant factor VIII-Fc fusion protein (rFVIIIFc) was constructed to determine the potential for reduced frequency of dosing. rFVIIIFc has an ∼ 2-fold longer half-life than rFVIII...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Dumont, Jennifer A., Liu, Tongyao, Low, Susan C., Zhang, Xin, Kamphaus, George, Sakorafas, Paul, Fraley, Cara, Drager, Douglas, Reidy, Thomas, McCue, Justin, Franck, Helen W. G., Merricks, Elizabeth P., Nichols, Timothy C., Bitonti, Alan J., Pierce, Glenn F., Jiang, Haiyan
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2012
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3953019/
https://ncbi.nlm.nih.gov/pubmed/22246033
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-08-367813
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados